Spectral slope analysis. by Anika T. Löwe (19924021)

“…<p>A: The spectral slope significantly decreased from Wake to N1 to N2, as expected. …”

Summary of subgroup analysis results. by Yongki Welliam (21030005)

“…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”

PRISMA Flow Chart 2020. by Yongki Welliam (21030005)

“…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”

Included and excluded studies. by Yongki Welliam (21030005)

“…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”

Characteristics of included studies. by Yongki Welliam (21030005)

“…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”

Extraction data table. by Yongki Welliam (21030005)

“…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”

Prevalence of CSF biomarkers across age. by Sarah J. Neal (20721301)

Interpretation of findings of the present study. by Rayane Brinck Teixeira (6676529)

Figure S5 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity by Priyanka S. Rana (15136410)

“…CD8+ T-cells were treated with compound A for 24 h after which they were assessed for surface expression of PD-1, TIM-3, CTLA-4, and LAG-3. Compound A induced a marked decrease in PD-1 surface expression, while no significant change was observed in TIM-3, CTLA-4, and LAG-3.…”

VisAccel complete data_redacted2.xlsx by Miguel A. Yakouma (21439852)

“…When the visual stimulus was inverted so it was inconsistent with the inertial motion, the respective biases were 6.5 ± 1.5°, 5.6 ± 1.7°, and 5.9 ± 2.0°. The biases with the inverted stimulus were significantly smaller (p < 0.0001), demonstrating that the visual motion profile is considered in multisensory integration rather than simple trajectory endpoints.…”

Table 1_Global burden of reported lower respiratory system fungal infection.docx by Zheng Wang (25883)

Table 1_Gut microbiota dysbiosis in ankylosing spondylitis: a systematic review and meta-analysis.docx by Qin-Yi Su (14188151)

“…In terms of specific microbial families, we observed a significant decrease in the abundance of Bifidobacterium (SMD = -0.42, 95% CI: -2.37, 1.52; P < 0.001), which is known for its beneficial effects on gut health. …”

Clinical and biochemical determinants of length of stay, readmission and recurrence in patients admitted with diabetic ketoacidosis by Fateen Ata (12217764)

“…None of the factors were significantly associated with 90-day readmission. Patients with pre-existing T1DM were more likely to have a six-month DKA recurrence than pre-existing T2DM. …”

Data Sheet 1_CaMYBA–CaMYC–CaTTG1 complex activates the transcription of anthocyanin synthesis structural genes and regulates anthocyanin accumulation in pepper (Capsicum annuum L.)... by Xiaowei Ma (113432)

“…The role of CaMYBA–CaMYC–CaTTG1 complex in anthocyanin biosynthesis in pepper leaves was studied. …”

Data Sheet 1_ESAT-6 protein suppresses allograft rejection by inducing CD4+Foxp3+ regulatory T cells through IκBα/cRel pathway.docx by Xiaofei Huang (2262337)

“…ESAT-6 augmented the percentage of CD4⁺Foxp3⁺ Tregs, whereas it decreased the frequency of Th1 and CD4⁺/CD8⁺ effector T cells in spleen and lymph nodes (LNs) posttransplantation. …”

Data Sheet 1_Low CD46 expression on activated CD4+ T cells predict improved Th1 cell reactivity to calcitriol in majority of patients with allergic eosinophilic asthma and healthy... by Julie Stichova (19729855)

“…The calcitriol-induced regulatory effect manifested by a stronger surface decrease of CD46 on activated CD4⁺ T cells (by 40% in HDs and by 26% in AEA), accompanied by a significant inhibition of IFN-γ and increased IL-10 production (by 31% in HDs and by 85% in AEA). …”

Application to actual brain network functional states. by Remy Ben Messaoud (20521877)

Data Sheet 1_Effects of aging on otolith morphology and functions in mice.docx by Keita Ueda (19855536)

“…Significant differences were also observed in the amplitude of the eye movement during the vestibulo-ocular reflex induced by linear acceleration (maximum amplitude of stimulation = 1.3G [p = 0.014]; maximum amplitude of stimulation = 0.7G [p = 0.015]), indicating that the otolith function was worse in old mice than in young mice.…”

Effects of Continuous Glucose Monitoring on Impaired Awareness of Hypoglycemia in Older Adults With Type 1 Diabetes: A Post Hoc Analysis of the WISDM Study by Anika Bilal (16701942)

“…IAH was assessed using the Clarke-full score and its subscales: Hypoglycemia Awareness Factor (HAF) and Severe Hypoglycemia Experienced Factors (SHEF) at baseline, 26 weeks, and 52 weeks</p><p dir="ltr">Results: After 26(n=184) and 52 weeks(n=94) of CGM use, Clarke-SHEF decreased significantly (p=0.02 and p<0.0001 respectively) while Clarke-full and Clarke-HAF remained unchanged. …”

Table 1_Serum uric acid/creatinine ratio and 1-year stroke recurrence in patient with acute ischemic stroke and abnormal renal function: results from the Xi'an stroke registry stud... by Zhongzhong Liu (111119)

“…Compared to Q1, the Q2 and Q4 groups showed significantly reduced risk in 1-year stroke recurrence (Q2: HR = 0.46, 95% CI 0.27 to 0.79, P = 0.005; Q4: HR = 0.47, 95% CI 0.27 to 0.81, P = 0.007), with a significant trend across all quartiles (P = 0.01 for trend tests). …”